IRON Disc Medicine Corp: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Risks for Disc Medicine, Inc. (IRON) stem from a narrow development pipeline, where failures in blood research threaten a collapse in share prices. Meanwhile, laboratories operate strictly according to protocol, ensuring capacity readiness for synthesis. Growth prospects are driven by the success of bitopertin and DISC-0974, as well as interest from major pharma behemoths. The 12-month YoY change in net income per share on this GURU.Markets chart is -18.00, reflecting the EPS dynamics.
discmedicine.com - פילוחים אנליטיים ומדדי מפתח (IRON)

Year-over-year (TTM) EPS growth measures the dynamics of net income per share over twelve months, allowing for an assessment of actual capitalization efficiency and business growth momentum. For Disc Medicine, Inc. (IRON), the EPS YoY TTM shift reflects the extent to which AI-driven drug synthesis automation converts into financial results against the backdrop of clinical trial expenditures.